ATE445006T1 - Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung - Google Patents

Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung

Info

Publication number: ATE445006T1
Authority: AT; Austria
Prior art keywords: insulin; producing cells; exendin; glp; differentiation
Prior art date: 1998-08-10

Application number

AT99942066T

Other languages

English (en)

Inventor

Josephine Egan

Riccardo Perfetti

Antonino Passaniti

Nigel Greig

Harold Holloway

Original Assignee

Us Gov Health & Human Serv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-10

Filing date

1999-08-10

Publication date

2009-10-15

1999-08-10 Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE445006T1 publication Critical patent/ATE445006T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 11
229940125396 insulin Drugs 0.000 title abstract 6
108010011459 Exenatide Proteins 0.000 title abstract 3
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 3
229960001519 exenatide Drugs 0.000 title abstract 3
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 title 1
230000004069 differentiation Effects 0.000 title 1
102000004877 Insulin Human genes 0.000 abstract 5
108090001061 Insulin Proteins 0.000 abstract 5
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 2
239000003102 growth factor Substances 0.000 abstract 2
150000001413 amino acids Chemical group 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Developmental Biology & Embryology (AREA)
Biophysics (AREA)
Virology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)

AT99942066T 1998-08-10 1999-08-10 Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung ATE445006T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9591798P	1998-08-10	1998-08-10
PCT/US1999/018099 WO2000009666A2 (en)	1998-08-10	1999-08-10	Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof

Publications (1)

Publication Number	Publication Date
ATE445006T1 true ATE445006T1 (de)	2009-10-15

Family

ID=22254191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99942066T ATE445006T1 (de)	1998-08-10	1999-08-10	Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung

Country Status (10)

Country	Link
US (2)	US7056734B1 (de)
EP (2)	EP1105460B1 (de)
JP (4)	JP4624558B2 (de)
AT (1)	ATE445006T1 (de)
AU (1)	AU776514B2 (de)
CA (1)	CA2339326A1 (de)
DE (1)	DE69941510D1 (de)
DK (1)	DK1105460T3 (de)
ES (2)	ES2553108T3 (de)
WO (1)	WO2000009666A2 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6703017B1 (en)	1994-04-28	2004-03-09	Ixion Biotechnology, Inc.	Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US6699973B1 (en) *	1998-11-19	2004-03-02	Elan Corporation, Plc	Antibodies to peptides that target GIT receptors and related methods
US6242666B1 (en) *	1998-12-16	2001-06-05	The Scripps Research Institute	Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US6967019B2 (en) *	1999-04-06	2005-11-22	The Regents Of The University Of California	Production of pancreatic islet cells and delivery of insulin
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US20030082155A1 (en) *	1999-12-06	2003-05-01	Habener Joel F.	Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6448045B1 (en) *	2000-03-10	2002-09-10	The Regents Of The University Of California	Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
EP1274720A4 (de)	2000-04-12	2004-08-18	Human Genome Sciences Inc	Albumin enthaltende fusionsproteine
EP1346722B1 (de)	2000-12-01	2008-12-10	Takeda Pharmaceutical Company Limited	Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
JP2005501058A (ja)	2001-07-31	2005-01-13	ザガバメントオブザユナイテッドステイツオブアメリカアズリプレゼンテッドバイザセクレタリーデパートメントオブヘルスアンドヒューマンサービシーズザナショナルインステ	Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
US6642003B2 (en)	2001-08-02	2003-11-04	Cedars-Sinai Medical Center	Human glucose-dependent insulin-secreting cell line
US6911324B2 (en)	2001-10-18	2005-06-28	The Regents Of The University Of California	Induction of beta cell differentiation in human cells
EP1453954A4 (de) *	2001-11-09	2004-12-15	Artecel Sciences Inc	Endokrine pankreasdifferenzierung von aus fettgewebe stammenden stromazellen und ihre verwendung
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
CA2476589C (en) *	2002-02-27	2014-02-25	Pharmain, Ltd.	Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
US20060122104A1 (en) *	2002-05-28	2006-06-08	Presnell Sharon C	Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
US7427415B2 (en)	2002-10-11	2008-09-23	Novocell, Inc.	Implantation of encapsulated biological materials for treating diseases
AU2003283216A1 (en) *	2002-12-03	2004-06-23	Novo Nordisk A/S	Combination treatment using exendin-4 and thiazolidinediones
EP1688148A1 (de) *	2002-12-03	2006-08-09	Novo Nordisk A/S	Behandlung mit Kombinationspräparaten aus Exendin-4 und Thiazolidindionen
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
ATE502665T1 (de)	2003-02-04	2011-04-15	Novo Nordisk As	Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
CA2518465A1 (en)	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
ATE437941T1 (de) *	2003-06-20	2009-08-15	Vrije Universiteit Brussel Vub	Verfahren zur erzeugung von beta-inselzellen aus exokrinen pankreaszellen
US9572840B2 (en)	2003-06-27	2017-02-21	DePuy Synthes Products, Inc.	Regeneration and repair of neural tissue using postpartum-derived cells
US8790637B2 (en)	2003-06-27	2014-07-29	DePuy Synthes Products, LLC	Repair and regeneration of ocular tissue using postpartum-derived cells
ES2564044T3 (es)	2003-06-27	2016-03-17	DePuy Synthes Products, Inc.	Células posparto derivadas de tejido del cordón umbilical y métodos de preparación y uso de las mismas
US9592258B2 (en)	2003-06-27	2017-03-14	DePuy Synthes Products, Inc.	Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
PT1723128E (pt)	2004-01-06	2013-02-27	Novo Nordisk As	Heteroaril-ureias e o seu uso como activadores da glicoquinase
ES2642214T3 (es)	2004-01-21	2017-11-15	Novo Nordisk Health Care Ag	Conjugación de péptidos mediante transglutaminasa
WO2005112977A2 (en) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
JPWO2005118781A1 (ja) *	2004-06-03	2008-04-03	国立大学法人京都大学	インスリン分泌細胞の誘導
US8148412B2 (en)	2004-12-03	2012-04-03	Novo Nordisk A/S	Heteroaromatic glucokinase activators
BRPI0612996A2 (pt)	2005-07-14	2010-12-14	Novo Nordisk As	ativadores de urÉia glucocinase
AU2006290205B2 (en)	2005-09-14	2012-12-13	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors for treating diabetes
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN101374946B (zh)	2005-12-16	2017-07-18	伊西康公司	用于在组织相容性不匹配的移植中抑制有害的免疫反应的组合物和方法
EP1971372B1 (de)	2005-12-19	2018-11-14	PharmaIN Corporation	Trägerzusammensetzungen mit hydrophobem kern zur abgabe von therapeutischen mitteln, herstellungs- und anwendungsverfahren damit
US8178495B2 (en)	2008-06-27	2012-05-15	Duke University	Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US9125906B2 (en)	2005-12-28	2015-09-08	DePuy Synthes Products, Inc.	Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US20090054305A1 (en)	2006-03-15	2009-02-26	Novo Nordisk A/S	Mixtures of Amylin and Insulin
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2008204530B2 (en)	2007-01-11	2013-08-01	Vtv Therapeutics Llc	Urea glucokinase activators
RU2413528C2 (ru)	2007-01-18	2011-03-10	Открытое Акционерное Общество "Валента Фармацевтика"	Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US20100216691A1 (en)	2007-07-16	2010-08-26	Novo Nordisk A/S	Protease Stabilized, Pegylated Insulin Analogues
US7960336B2 (en)	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009109927A2 (en) *	2008-03-05	2009-09-11	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
WO2009115469A1 (en)	2008-03-18	2009-09-24	Novo Nordisk A/S	Protease stabilized, acylated insulin analogues
BRPI0923068B1 (pt)	2008-12-19	2021-05-25	Advanced Technologies And Regenerative Medicine, Llc	Uso de células derivadas de tecido de cordão umbilical para tratar um paciente tendo uma doença, distúrbio ou injúria pulmonar
US10179900B2 (en)	2008-12-19	2019-01-15	DePuy Synthes Products, Inc.	Conditioned media and methods of making a conditioned media
CN102498204B (zh)	2009-03-26	2015-02-04	德普伊新特斯产品有限责任公司	人脐带组织细胞作为用于阿尔茨海默病的疗法
CN101991580B (zh) *	2009-08-28	2013-03-20	杏辉天力（杭州）药业有限公司	以羊毛甾烷及茯苓萃取物治疗糖尿病的用途
WO2011064316A2 (en)	2009-11-25	2011-06-03	Paolo Botti	Mucosal delivery of peptides
CA2797133C (en)	2010-04-27	2019-08-06	Zealand Pharma A/S	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
CN109593814A (zh)	2010-05-12	2019-04-09	哥伦比亚大学纽约管理委员会	筛选分析、鉴别药剂的方法及药物组合物
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
JP6301263B2 (ja)	2011-12-23	2018-03-28	デピュイ・シンセス・プロダクツ・インコーポレイテッド	ヒト臍帯組織由来細胞の検出
MX356957B (es)	2012-07-23	2018-06-20	Zealand Pharma As	Analogos del glucagon.
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
LT3057984T (lt)	2013-10-17	2018-12-27	Zealand Pharma A/S	Acilinti gliukagono analogai
AU2014345569B2 (en)	2013-11-06	2020-08-13	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080150B1 (de)	2013-12-13	2018-08-01	Sanofi	Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2015162485A1 (en) *	2014-04-22	2015-10-29	Txp Pharma Gmbh	Peptide analogues with branched amino acid probe(s)
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
US10487314B2 (en)	2014-06-26	2019-11-26	The Trustees Of Columbia University In The City Of New York	Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
RU2573933C1 (ru)	2014-08-21	2016-01-27	Дафот Энтерпрайсис Лимитед	Пептид для лечения сахарного диабета 2-го типа и его осложнений
RU2716985C2 (ru)	2014-10-29	2020-03-17	Зилэнд Фарма А/С	Соединения-агонисты gip и способы
JP6989385B2 (ja)	2015-04-16	2022-01-05	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
SG10201911851VA (en)	2016-12-09	2020-02-27	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists
CN109679964A (zh) *	2019-01-12	2019-04-26	青岛华义宏博生物科技有限公司	一种表达人胰岛素基因的重组乳酸乳球菌
EP3938037A1 (de)	2019-03-15	2022-01-19	Diet4Life ApS	Kombination von diätetischen peptiden

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
AU4114493A (en) *	1992-04-24	1993-11-29	Polymer Technology Group, Inc., The	Method of culturing viable cells and method of regulating the level of a compound in a body fluid
SK155694A3 (en)	1992-06-15	1995-05-10	Pfizer	Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
NZ250844A (en)	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2137206A1 (en)	1993-12-09	1995-06-10	John A. Galloway	Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
DE69739172D1 (de) *	1996-08-08	2009-01-29	Amylin Pharmaceuticals Inc	Regulation gastrointestinaler beweglichkeit
WO1999043705A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
AU5027299A (en)	1998-07-31	2000-02-28	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes

1999
- 1999-08-10 JP JP2000565103A patent/JP4624558B2/ja not_active Expired - Fee Related
- 1999-08-10 EP EP99942066A patent/EP1105460B1/de not_active Expired - Lifetime
- 1999-08-10 ES ES08019260.2T patent/ES2553108T3/es not_active Expired - Lifetime
- 1999-08-10 CA CA002339326A patent/CA2339326A1/en not_active Abandoned
- 1999-08-10 WO PCT/US1999/018099 patent/WO2000009666A2/en not_active Ceased
- 1999-08-10 EP EP08019260.2A patent/EP2028269B1/de not_active Expired - Lifetime
- 1999-08-10 US US09/762,538 patent/US7056734B1/en not_active Expired - Fee Related
- 1999-08-10 ES ES99942066T patent/ES2335066T3/es not_active Expired - Lifetime
- 1999-08-10 AU AU55524/99A patent/AU776514B2/en not_active Ceased
- 1999-08-10 AT AT99942066T patent/ATE445006T1/de active
- 1999-08-10 DK DK99942066.4T patent/DK1105460T3/da active
- 1999-08-10 DE DE69941510T patent/DE69941510D1/de not_active Expired - Lifetime
2006
- 2006-04-07 US US11/400,715 patent/US20070041951A1/en not_active Abandoned
2007
- 2007-04-24 JP JP2007114374A patent/JP4755133B2/ja not_active Expired - Fee Related
2009
- 2009-08-07 JP JP2009184807A patent/JP2009291206A/ja active Pending
2011
- 2011-04-05 JP JP2011083828A patent/JP2011177181A/ja active Pending

Also Published As

Publication number	Publication date
ES2335066T3 (es)	2010-03-18
WO2000009666A3 (en)	2000-11-23
CA2339326A1 (en)	2000-02-24
JP2002522068A (ja)	2002-07-23
US20070041951A1 (en)	2007-02-22
US7056734B1 (en)	2006-06-06
JP2007209348A (ja)	2007-08-23
JP4624558B2 (ja)	2011-02-02
DE69941510D1 (de)	2009-11-19
ES2553108T3 (es)	2015-12-04
EP1105460B1 (de)	2009-10-07
JP2011177181A (ja)	2011-09-15
EP2028269B1 (de)	2015-10-21
EP2028269A1 (de)	2009-02-25
JP4755133B2 (ja)	2011-08-24
AU776514B2 (en)	2004-09-09
WO2000009666A9 (en)	2000-07-13
AU5552499A (en)	2000-03-06
JP2009291206A (ja)	2009-12-17
EP1105460A2 (de)	2001-06-13
WO2000009666A2 (en)	2000-02-24
DK1105460T3 (da)	2010-02-08

Legal Events

Date

Code

Title

Description

2010-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1105460

Country of ref document: EP

Publication	Publication Date	Title
DE69941510D1 (de)	2009-11-19	Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
DE69532914D1 (de)	2004-05-27	Glucagonähnliche, insulinotrope Komplexe, ihre Zusammensetzungen und ihr Herstellungsverfahren
TR199802252T2 (xx)	1999-02-22	N�ral ve renal geli�menin uyar�lmas� i�in ret ligand� (RetL)
WO2003014318A3 (en)	2006-08-03	Methods for treating diabetes and other blood sugar disorders
DE69333112D1 (de)	2003-08-28	Modifizierte pilzzellen und methode zur herstelllung rekombinanter produkte
DE69225432D1 (de)	1998-06-18	A-C-B-Proinsulin, Verfahren zu seiner Herstellung und Verwendung, und Zwischenprodukte in der Insulin-Produktion
DE23193606T1 (de)	2024-02-15	Verfahren zur erhöhung der funktion eines aav-vektors
DE68926892D1 (de)	1996-09-05	Verfahren zur Herstellung von Zellen, die stabil integrierte fremde DNS mit hoher Kopiezahl enthalten, durch dieses Verfahren hergestellte Zellen und Verwendung dieser Zellen zur Herstellung von durch diese fremde DNS kodierten Polypeptiden
ATE400651T1 (de)	2008-07-15	Verwendung von grünem fluoreszenzprotein
ATE251465T1 (de)	2003-10-15	In-vitro stimulation von beta zellen vermehrung
ATE138101T1 (de)	1996-06-15	Dna-fragment, das ein polypeptid mit nitrilhydrataseaktivität kodiert, dna-fragment enthaltende transformante und verfahren zur herstellung von amiden unter verwendung der transformante
SG155250A1 (en)	2009-09-30	PRODUCTION OF a-ABETA
PT955313E (pt)	2006-07-31	Nova proteina e processo para a sua producao
ATE178354T1 (de)	1999-04-15	Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
ATE401413T1 (de)	2008-08-15	Verfahren zur herstellung von l-aminosäuren, unter verwendung von stämmen aus der familie der enterobacteriaceae, welche ein attenuiertes acea- gen enthalten
ES2063834T3 (es)	1995-01-16	Tgf-beta 1/beta 2: un nuevo factor del crecimiento-beta transformante quimerico.
ATE502305T1 (de)	2011-04-15	Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik
ATE233815T1 (de)	2003-03-15	Mutanten der formiatdehydrogenase aus candida biodinii, gensequenzen diese codierend sowie verwendung dieser formiatdeydrogenasen
ATE247164T1 (de)	2003-08-15	Insulinartigen wachstumsfaktor bindendes protein
DE69728654D1 (de)	2004-05-19	Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE69433221D1 (de)	2003-11-13	Neues Chondrozytprotein
DE10214653A1 (de)	2003-03-27	Ein Verfahren zur Herstellung einer Gen-Bank mutierter Proteine mit unterschiedlichen Größen und unterschiedlichen Sequenzen
DE1929T1 (de)	1980-07-24	Synthetische DNA und Verfahren zu ihrer Herstellung
Baumgartner et al.	1980	Amino acid sequences in crotalase, a thrombin-like enzyme from the venom of Crotalus adamanteus
DE69733571D1 (de)	2005-07-21	Eine methode zur erhöhung der transfektion von zellen